Drug
Simufilam clinical trials
Also written PTI-125.
- studies test it
- 10
- open now
- 0
- in phase 3
- 3
- first study started
- 2019
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 2 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 4
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
Studies
Open first, then newest update. How each study uses Simufilam is read from its arms, and is right about nine times in ten.
Testing it · 10
- Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's DiseaseTerminatedPhase 3Cassava Sciences, Inc.NCT05026177Written as Simufilam
- Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's DiseaseTerminatedPhase 2Cassava Sciences, Inc.NCT05352763Written as simufilam
- Simufilam 100 mg for Mild-to-Moderate Alzheimer's DiseaseCompletedPhase 3Cassava Sciences, Inc.NCT04994483Written as Simufilam
- Open-label Extension for Phase 3 Clinical Trials of SimufilamTerminatedPhase 3Cassava Sciences, Inc.NCT05575076Written as Simufilam
- Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease PatientsCompletedPhase 2Cassava Sciences, Inc.NCT04388254Written as Simufilam 100 mg oral tablet
- Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male SubjectsCompletedPhase 1Cassava Sciences, Inc.NCT06195319Written as Simufilam
- A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic FunctionCompletedPhase 1Cassava Sciences, Inc.NCT06390410Written as Simufilam
- Food Effect and Bioequivalence Study of Simufilam Tablets in Healthy VolunteersCompletedPhase 1Cassava Sciences, Inc.NCT04932655Written as simufilam
- PTI-125 for Mild-to-moderate Alzheimer's Disease PatientsCompletedPhase 2Cassava Sciences, Inc.NCT04079803Written as Simufilam 100 mg tablet
- PTI-125 for Mild-to-moderate Alzheimer's Disease PatientsCompletedPhase 2Pain TherapeuticsNCT03748706Written as PTI-125, 100 mg tablets
Codes
What other systems call Simufilam · ClinicalTrials.gg INT001716
- MeSH (NLM) C000719508SimufilamConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 6NV440YIO0SIMUFILAMConfirmed FDA, NLM, Wikidata
- Wikidata Q111669700simufilamConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C180661SimufilamOne source FDA
- DrugBank DB18817One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000719508 | Simufilam | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 6NV440YIO0 | SIMUFILAM | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q111669700 | simufilam | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C180661 | Simufilam | One source FDA |
| DrugBank | DB18817 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.